EE173 Economic Evaluation of Exagamglogene Autotemcel (EXA-CEL) Gene-Edited Therapy in Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises
C. Udeze(Vertex Pharmaceuticals (United States)), A. Lopez(Vertex Pharmaceuticals (United States)), Hongbo Yang(Analysis Group (United States)), Urvi Mujumdar(Memorial Sloan Kettering Cancer Center), N. Li(Vertex Pharmaceuticals (United States)), Jing Wang(Sun Yat-sen University), Yang Xie(Tianjin Medical University General Hospital), F.J. Ogunsile(Memorial Regional Hospital), Shanmugam M. Jeyakumar(Vertex Pharmaceuticals (United States))
Cited by 3
Related Papers
ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma
|Theranostics|2020|162
Interrogating glioma-M2 macrophage interactions identifies Gal-9/Tim-3 as a viable target against <i>PTEN</i> -null glioblastoma
|Science Advances|2022|141
Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2
|Cell Reports|2017|129
The phosphatidylinositol 3-kinase/Akt and c-Jun N-terminal kinase signaling in cancer: Alliance or contradiction? (Review)
|International Journal of Oncology|2015|128